Project Grant R43HL186097
Award Date 8/5/26
Completion Date 7/31/27
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Cambridge, MA 02141, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Prenosis, Inc. $1,218,102 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate the Heart Failure CardioScore, an artificial intelligence diagnostic tool for acute heart failure in emergency department patients. Prenosis will combine novel biomarkers and clinical data with machine learning to improve diagnostic and prognostic accuracy for acute heart failure, addressing the challenge...
- The National Heart, Lung, and Blood Institute awarded Icardio.ai Corporation $290,142 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, for an artificial intelligence-enabled diagnostic support system for echocardiography. Performance of the award concludes on August 31, 2027, at the recipient's location in Century City, California. The project addresses the shortage of trained echocardiographers and the infrastructure constraints that limit adoption of...
- The National Heart, Lung, and Blood Institute awarded Talk Story Health LLC $550,000 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. Talk Story Health LLC will develop and test BEAT-TO-BEAT, an AI-powered digital health intervention designed to improve cardiovascular health outcomes in rural communities with limited healthcare access. The project delivers three interconnected components: a Cardiovascular Information Engine (CIE) trained on validated...
- The National Heart, Lung, and Blood Institute awarded $305,471 to ISA Associates, Inc. on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and pilot test a mobile stress management and medication adherence intervention targeting hypertension among men employed in manual and trade labor. The project addresses occupational stress as a driver of hypertension risk in construction, repair, production, and transportation workers, who experience...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded Tele-Stethoscope Inc. $406,367 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop Phase I algorithms and demonstrate technical feasibility for a mobile phone–based diagnostic tool that uses acoustic data to predict clinically significant spirometry and echocardiogram findings. The recipient will develop algorithms for predicting FEV1 percent predicted findings using mobile phone–captured...
- The National Heart Lung and Blood Institute awarded Precisionbio AI, LLC $374,472 on September 1, 2026, to develop a machine learning-driven precision dosing system for warfarin anticoagulation therapy under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will develop and validate a predictive platform that integrates lifestyle, clinical, and pharmacogenomic data through a multi-model ensemble combining interpretable machine learning models with deep neural networks and...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $593,985 on September 15, 2025, under Cardiovascular Diseases Research (CFDA 93.837) to develop artificial intelligence techniques that convert photoplethysmography measurements from off-the-shelf wearable devices into multi-lead electrocardiogram signals for real-time evaluation of acute myocardial infarction outside clinical settings. The project addresses a clinical gap: while electrocardiography is the gold...